These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15661809)

  • 1. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer.
    Belinsky SA
    Carcinogenesis; 2005 Sep; 26(9):1481-7. PubMed ID: 15661809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-promoter hypermethylation as a biomarker in lung cancer.
    Belinsky SA
    Nat Rev Cancer; 2004 Sep; 4(9):707-17. PubMed ID: 15343277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene promoter hypermethylation in mouse lung tumors.
    Vuillemenot BR; Hutt JA; Belinsky SA
    Mol Cancer Res; 2006 Apr; 4(4):267-73. PubMed ID: 16603640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene silencing by DNA methylation in haematological malignancies.
    Boultwood J; Wainscoat JS
    Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer.
    Luxen S; Belinsky SA; Knaus UG
    Cancer Res; 2008 Feb; 68(4):1037-45. PubMed ID: 18281478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
    Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
    Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results.
    Digel W; Lübbert M
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):1-11. PubMed ID: 15886007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of the MGMT gene in cancer.
    Soejima H; Zhao W; Mukai T
    Biochem Cell Biol; 2005 Aug; 83(4):429-37. PubMed ID: 16094446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.
    Tessema M; Willink R; Do K; Yu YY; Yu W; Machida EO; Brock M; Van Neste L; Stidley CA; Baylin SB; Belinsky SA
    Cancer Res; 2008 Mar; 68(6):1707-14. PubMed ID: 18339850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer.
    Marsit CJ; Okpukpara C; Danaee H; Kelsey KT
    Mol Carcinog; 2005 Oct; 44(2):146-50. PubMed ID: 16013053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer.
    Fukui T; Kondo M; Ito G; Maeda O; Sato N; Yoshioka H; Yokoi K; Ueda Y; Shimokata K; Sekido Y
    Oncogene; 2005 Sep; 24(41):6323-7. PubMed ID: 16007200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
    Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
    Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors.
    Reamon-Buettner SM; Borlak J
    Cancer Res; 2008 Sep; 68(18):7587-96. PubMed ID: 18794147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.
    Toyota M; Suzuki H; Sasaki Y; Maruyama R; Imai K; Shinomura Y; Tokino T
    Cancer Res; 2008 Jun; 68(11):4123-32. PubMed ID: 18519671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
    Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
    Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
    Baylin SB; Ohm JE
    Nat Rev Cancer; 2006 Feb; 6(2):107-16. PubMed ID: 16491070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
    Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
    Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.